[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metabolic-cardiovascular-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metabolic-cardiovascular-syndrome":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100258681","phase-1-metabolic-effects-of-angiotensin-1-7-100258681",false,"NCT02646475","Metabolic Effects of Angiotensin-(1-7)","Inclusion Criteria:\n\n* Males and females of all races between 18 and 60 years of age\n* Obesity defined as body mass index between 30-40 kg\u002Fm2\n* Insulin resistance defined as homeostasis model assessment 2 insulin resistance (HOMA2-IR) score \\>2.2\n* Hypertension defined by two or more properly measured seated blood pressure readings \\>130\u002F85 mmHg, or by use of anti-hypertensive medications. This blood pressure cutoff will allow us to include subjects with pre-hypertension.\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Pregnancy or breast-feeding\n* Current smokers or history of heavy smoking (\\>2 packs\u002Fday)\n* History of alcohol or drug abuse\n* Morbid obesity (BMI \\> 40 kg\u002Fm2)\n* Previous allergic reaction to study medications\n* Evidence of type I or type II diabetes (i.e. fasting glucose \\>126 mg\u002Fdl, use of anti-diabetic medications)\n* Cardiovascular disease other than hypertension such as myocardial infarction within 6 months prior to enrollment, presence of angina pectoris, significant arrhythmia, congestive heart failure (LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, or hypertrophic cardiomyopathy\n* History of serious cerebrovascular disease such as cerebral hemorrhage, stroke, or transient ischemic attack\n* History or presence of immunological or hematological disorders\n* Impaired hepatic function \\[aspartate amino transaminase (AST) and\u002For alanine amino transaminase (ALT) \\> 2.0 x upper limit of normal range\\]\n* Impaired renal function (serum creatinine \\>1.5 mg\u002Fdl)\n* Anemia (hemoglobin \\\u003C13.5 g\u002Fdl in males or \\\u003C12.5 g\u002Fdl in females)\n* Treatment with serotonin-norepinephrine reuptake inhibitors (SNRIs) or norepinephrine transporter (NET) inhibitors\n* Treatment with phosphodiesterase 5 inhibitors\n* Treatment with anticoagulants\n* Treatment with chronic systemic glucocorticoid therapy (more than 7 consecutive days in 1 month)\n* Treatment with any investigational drug in the 1 month preceding the study\n* Inability to give, or withdraw, informed consent\n* Other factors which in the investigator's opinion would prevent the subject from completing the protocol (i.e., clinically significant abnormalities on clinical, mental examination or laboratory testing or inability to comply with protocol)","ALL","18 Years","60 Years",{"count":19,"type":20},26,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The overall purpose of this study is to learn more about the metabolic effects of angiotensin-(1-7) in the insulin resistant state associated with obesity. Pharmacologic approaches to increase angiotensin-(1-7) levels or its actions are currently in development for treatment of metabolic-related diseases such as obesity and type II diabetes, based on findings from animal studies. It is unclear if this peptide contributes to the regulation of metabolism in humans. The investigators will test if angiotensin-(1-7) infusion can improve insulin sensitivity measured by hyperinsulinemic-euglycemic clamp methods in individuals with obesity and insulin resistance. The investigators will also examine for changes in blood pressure and related hemodynamic and hormonal changes following angiotensin-(1-7) infusion.",[26,27,28,29],"Obesity","Insulin Resistance","Hypertension","Metabolic Cardiovascular Syndrome",[31,32,33,34],"renin-angiotensin system","angiotensin","insulin resistance","blood pressure","RECRUITING","2026-05-18",{"date":38,"type":39},"2026-05-22","ACTUAL",{"date":41,"type":39},"2016-02",{"date":43,"type":20},"2029-12",{"name":45,"class":46},"Vanderbilt University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":56,"targetDuration":58,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":47},"100588329","cardiometabolic-evaluation-registry-of-heart-failure-100588329","NCT06939985","Cardiometabolic evalUation REgistry of Heart Failure","Cardiometabolic Risk Factors and Clinical Outcomes in Heart Failure: An Observational Cohort Study","CURE-HF","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Chronic HF (NYHA II\\~IV), including:\n\n   * HFrEF (HF with reduced ejection fraction): ① HF symptoms±signs ; ② LVEF≤40%.\n   * HFimpEF (HF with improved ejection fraction): ① HF symptoms±signs; ② previous LVEF ≤ 40% and a follow-up measurement of LVEF \\>40%.\n   * HFmrEF (HF with mildly reduced ejection fraction): ① HF symptoms±signs; ② LVEF 41%\\~49%.\n   * HFpEF (HF with preserved ejection fraction): ① HF symptoms±signs; ② LVEF ≥50%; ③ objective evidence of cardiac structural and\u002For functional abnormalities consistent with the presence of LV diastolic dysfunction\u002Fraised LV filling pressures, including raised natriuretic peptide.\n\nExclusion Criteria:\n\n1. Estimated survival ≤ 1 year.\n2. Pregnant or lactation, or have the intention to give birth within one year.\n3. Poor compliance, unable to follow-up.\n4. Mental or physical status not allowing written informed consent.\n5. Unwillingness to give informed consent.",{"count":57,"type":20},5000,"5 Years","OBSERVATIONAL","This is a combined retrospective-prospective observational cohort study investigating the role of systemic and local cardiometabolic risk factors in cardiac structural\u002Ffunctional remodeling and clinical outcomes among heart failure (HF) patients. The study integrates retrospective clinical data (from the past 10 years) and prospective longitudinal follow-up (5 years) of HF patients across HF with reduced (HFrEF), mildly-reduced (HFmrEF), preserved (HFpEF) and improved ejection fraction (HFimpEF) phenotypes. Systemic metabolic factors (e.g., blood lipid profiles, glycemic levels, insulin resistance) and local factors (e.g., epicardial adipose tissue \\[EAT\\], perivascular adipose tissue \\[PVAT\\]) will be analyzed for their associations with changes in cardiac geometrics and function, dynamic transitions between HF phenotypes, as well as the occurrence of major adverse cardiovascular events (MACEs). The study seeks to advance risk stratification by integrated evaluation of cardiometabolic profiles so as to refine personalized cures in HF management.",[62,29,63],"Heart Failure","Metabolic Diseases",[65,66,67,68,69,70],"heart failure","cardiometabolic risk factors","epicardial adipose tissue","cardiac remodeling","heart failure phenotypes","major adverse cardiovascular events","2025-04-18",{"date":73,"type":39},"2025-04-23",{"date":75,"type":39},"2015-01-01",{"date":77,"type":20},"2030-05-31",{"name":79,"class":46},"Ruijin Hospital"]